Thrombophob is a combination of two medicines used to treat superficial thrombophlebitis (inflammation or swelling of a vein due to a blood clot). It helps to relieve pain and inflammation by speeding up the healing process.
Thrombophob gel/ointment is also used to treat bruises and hematoma (collection of blood under the skin). It speeds up the dissolution of the blood clot, decreasing the pain and swelling. This medicine is for external use only. The affected area must be clean and dry before applying this medicine. Make sure to wash your hands before and after applying this medicine.
Thrombophob is product from Cadila Healthcare Ltd (Zydus Cadila) is an Indian pharmaceutical company headquartered in Ahmedabad, Gujarat, India. The company is one of the leading pharmaceutical companies in India. It is a manufacturer of generic drugs.
Phlebitis is the inflammation of a vein. Veins are blood vessels in your body that carry blood from your organs and limbs back to your heart. If a blood clot is causing the inflammation, it’s called thrombophlebitis. When the blood clot is in a deep vein, it’s called deep vein thrombophlebitis, or deep vein thrombosis (DVT).
Potentially Fatal: Heparin-induced thrombocytopenia with or without thrombosis; bleeding.
Warnings and Precautions
Thrombocytopenia has been reported to occur in patients receiving Heparin with a reported incidence of 0 to 30%. Platelet counts should be obtained at baseline and periodically during Heparin administration. Mild thrombocytopenia (count greater than 100,000/mm3) may remain stable or reverse even if Heparin is continued. However, thrombocytopenia of any degree should be monitored closely. If the count falls below 100,000/mm3 or if recurrent thrombosis develops, the Heparin product should be discontinued, and if necessary, an alternative anticoagulant administered.
Delayed Onset of HIT and HITT
Heparin-induced Thrombocytopenia and Heparin-induced Thrombocytopenia and Thrombosis can occur up to several weeks after the discontinuation of Heparin therapy. Patients presenting with thrombocytopenia or thrombosis after discontinuation of Heparin should be evaluated for HIT and HITT.
Use in Neonates
Carefully examine all Heparin Sodium Injection vials and cartridges to confirm choice of the correct strength prior to administration of the drug. Pediatric patients, including neonates, have died as a result of medication errors in which Heparin Sodium Injection vials have been confused with “catheter lock flush” vials.
Increased resistance to Heparin is frequently encountered in fever, thrombosis, thrombophlebitis, infections with thrombosing tendencies, myocardial infarction, cancer, and in postsurgical patients.
Increased Risk to Older Patients, Especially Women
A higher incidence of bleeding has been reported in patients, particularly women over 60 years of age.
Patients predisposed to active bleeding including thrombocytopenia, peptic ulcer disease, cerebrovascular disorders, haemorrhagic blood disorders, bacterial endocarditis, severe hypertension, oesophageal varices. Recent surgery at sites where haemorrhage would be an especial risk. Severe renal and hepatic impairment. Cerebral or subarachnoid haemorrhage, abdominal or thoracic bleeding into closed space, severe traumatic bleed, hepatic, renal, splenic or arterial injury, severe haemostatic defect, arterial thrombosis with heparin-associated thrombocytopenia. IM admin.
Pregnancy- Caution when used during pregnancy.
Lactation- Not excreted in breast milk
Geriatic- Higher incidence of bleeding in women older than 60 years of age.
Inhibited by zinc. Antiplatelet drugs e.g. aspirin and dipyridamole may precipitate bleeding.
Potentially Fatal: NSAIDs may increase risk of haemorrhage. Effect increased by dextrans, high doses of penicillin and cephalosporins, phenylbutazone, asparaginase. streptokinase and some contrast media.